

## [Hyoscine butylbromide](#)

Statut de médicament essentiel

Section:

[2. Medicines for pain and palliative care](#) [2.3. Medicines for other common symptoms in palliative care](#)

Codes ATC: [A03BB01](#)

Indication

Palliative care Code ICD11: [QC7A](#)

Type de médicament

Chemical agent

Type de liste

Liste de base

Formulations

**Parenteral > General injections > unspecified:** 20 mg per mL injection

Historique des statuts LME

Ajouté pour la première fois en 2013 ([TRS 985](#))

Sexe

Tous

Âge

Adolescents et adultes

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets.](#)

Wikipédia

[Hyoscine butylbromide](#)

DrugBank

[Hyoscine butylbromide \(Scopolamine butylbromide\)](#)

Résumé des preuves et recommandation du comité d'experts



Following a review of medicines for palliative care by the Expert Committee in 2013, hyoscine butylbromide was added to the core list of the EML for management of respiratory secretions in patients receiving palliative care. Although the evidence for the benefit to the patient of the use of antimuscarinic agents in prevention of accumulation of respiratory tract secretions during the dying phase was acknowledged as weak by the Expert Committee, the inclusion of hyoscine butylbromide (which, in contrast to the hydrobromide included for children, does not cross the blood-brain barrier) was supported.